Northern Trust Corp Has $1.39 Billion Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Northern Trust Corp lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 16.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,658,360 shares of the biopharmaceutical company's stock after purchasing an additional 3,431,248 shares during the quarter. Northern Trust Corp owned approximately 1.22% of Bristol-Myers Squibb worth $1,394,677,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Fairway Wealth LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at $28,000. Transce3nd LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $28,000. Comprehensive Financial Planning Inc. PA acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $34,000. Westend Capital Management LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $38,000. Finally, Tacita Capital Inc bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $39,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Price Performance

Shares of BMY traded up $0.95 during trading hours on Friday, hitting $50.56. 14,165,790 shares of the company were exchanged, compared to its average volume of 12,966,960. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The company has a market cap of $102.89 billion, a price-to-earnings ratio of -11.44, a P/E/G ratio of 2.07 and a beta of 0.41. The firm's fifty day moving average is $55.68 and its 200 day moving average is $56.37.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same quarter last year, the company posted ($4.40) EPS. On average, equities analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a dividend of $0.62 per share. The ex-dividend date was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 4.91%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 1,823 shares of the business's stock in a transaction on Friday, February 14th. The shares were purchased at an average cost of $54.84 per share, with a total value of $99,973.32. Following the acquisition, the executive vice president now owns 63,932 shares of the company's stock, valued at $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.09% of the company's stock.

Analyst Ratings Changes

BMY has been the topic of a number of recent analyst reports. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Piper Sandler started coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target for the company. Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Jefferies Financial Group lowered their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Finally, Citigroup upped their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb has an average rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.